Advertisement
Articles
Subscribe to Drug Discovery & Development Articles

The Lead

Two Anti-Ebola Vaccines in Historic Race

September 11, 2014 | by Cynthia Fox, Science Editor | Comments

One of the most rapidly fast-tracked vaccines in history— an anti-Ebola “ChAd3” vaccine— just started clinical trial in humans, and may be done as soon as November. But a second fast-tracked anti-Ebola vaccine— called an “rVSV” vaccine— is hot on its heels. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Extractor Optimized for Processing Medicinal Marijuana

September 9, 2014 9:30 am | by Dr. Kenneth James, Supercritical Fluid Technologies, Inc. | Comments

The need for pharmaceutical grade cannabis oil has increased as researchers continue to investigate its use for the treatment of various ailments such as muscle spasms, glaucoma, nausea, mood and behavioral disorders, sleep disorders and chronic pain. Read more...

TOPICS:

How Outsourcing Can Accelerate the Drug Development Process

September 4, 2014 10:36 am | by Matthew Weinberg, CEO, The Weinberg Group | Comments

Outsourcing is an old concept in the healthcare industry that has recently been applied to a new area: regulatory affairs. Traditionally conducted in-house, regulatory affairs is extremely critical to a product’s success. For certain companies, this entire function can and should be outsourced in its entirety, not just for discrete projects. Read more...

TOPICS:

ZMapp: Best Anti-Ebola Drug Yet

September 3, 2014 10:15 am | by Cynthia Fox, Science Editor | Comments

ZMapp, the experimental drug that may have already have saved a few patients in Africa, is the most effective anti-Ebola therapy yet, according to a recent Nature paper on rhesus macaques monkeys. Read more...           

TOPICS:
Advertisement

Accelerate Drug Development with Optimized Content Management

August 29, 2014 8:30 am | by Steve Scribner, Principal Consultant – Life Sciences, EMC Information Intelligence Group | Comments

Getting a new drug from the laboratory to the pharmacy takes years of testing, applications and information sharing. One way to shorten the drug development life cycle is to optimize content management. Read more...          

TOPICS:

The Future of Genome Analysis

August 28, 2014 9:30 am | by Maxim Mikheev, M.D., Ph.D., Co-Founder and Chief Technical Officer at BioDatomics | Comments

As technological improvements have changed the way we study the genome, the amount of data associated with a single DNA sample has increased exponentially. Surprisingly, throughout this evolution the hardware and software infrastructure supporting bioanalytics has barely changed. Read more...

TOPICS:

A ‘Second Revolution’ in Drug Discovery and Development

August 27, 2014 9:58 am | by Seth Lederman, M.D., CEO, Tonix Pharmaceuticals | Comments

Drugs can be discovered and developed in two very different ways: at an evolutionary pace and at a revolutionary pace. The “first revolution” in biological psychiatry took place in the 1950s, and now, in the 21st century, a “second revolution” of drug development and discovery is taking place, driven by repurposing. Read more...

TOPICS:

Drug Cured 16 of 16 Monkeys with Viral Ebola Relative

August 26, 2014 11:31 am | by Cynthia Fox, Science Editor | Comments

An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...                   

TOPICS:

‘The Pill’ Shrinks Ovaries, Cuts Egg Numbers

August 25, 2014 9:49 am | by Cynthia Fox, Science Editor | Comments

The birth control pill significantly affects ovarian reserve— or the number of immature eggs in a woman’s ovaries— which can be a predictor of future fertility, according to a team in Denmark. Read more...             

TOPICS:
Advertisement

The Case for Orphan Drugs

August 22, 2014 10:34 am | by Louise Rozik, Editor | Comments

Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D, with approximately one-third of all new medicines approved by the FDA in the past 5 years having been developed for the treatment of diseases that affect fewer than 200,000 Americans. Read more...

TOPICS:

Amid ALS Mania, Possible Drug Target Spotted

August 21, 2014 3:02 pm | by Cynthia Fox, Science Editor | Comments

As, all around them, everyone from Derek Jeter to the Kennedy family was dousing themselves in ice water for the ALS “Ice Bucket Challenge,” Harvard researchers announced last week they may have found an ALS therapy. Read more...      

TOPICS:

Rating U.S. Drug Development Programs

August 20, 2014 11:10 am | by Chris Plaford, CFA, Chief Executive Officer, Claravant Analytics LLC | Comments

According to industry estimates, the majority of drugs in development will never make it to FDA approval. While a lack of efficacy is often a key factor, many clinical programs are derailed due to avoidable setbacks that can cause delays and significantly increase costs. Read more...

TOPICS:

Small Molecules, Stem Cells Can Improve Hearing

August 18, 2014 3:14 pm | by Cynthia Fox, Science Editor | Comments

A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.

TOPICS:

Developing Multi-Functional Anti-Inflammatory Drugs

July 24, 2014 10:44 am | by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics | Comments

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

TOPICS:

Reoviruses: The Discovery of Their Potential in Cancer Therapeutics

July 17, 2014 10:23 am | by Brad Thompson, Ph.D., President and Chief Executive Officer of Oncolytics Biotech | Comments

Reoviruses - first isolated in 1951 - are benign viruses with an important property: they are oncolytic, meaning they are capable of infecting and destroying many kinds of cancer cells. The story of how this discovery was made is an exciting one. Read more...

TOPICS:

Centralized Data Management Improves Collaboration

July 15, 2014 11:16 am | by Dr. Paul Denny-Gouldson, VP of Strategic Solutions at IDBS | Comments

Inventiva, a recent spin-off from Abbott, is a French biotech company specializing in running and managing integrated drug discovery partnerships from target validation up to clinical candidate selection who realized that it would benefit from having a more integrated data processing system across its multiple laboratories. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading